This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

British rider Tim Shoreman of Wheelbase Cabtech Castelli claimed victory on Stage 2 of the Rás Tailteann after surviving the decisive attacks and producing the strongest finish from the elite lead ...

The Higher Education Commission of Pakistan (HEC) on Monday announced the launch of a “fully online and paperless” degree attestation system to facilitate students. In December last year, the HEC said ...

Children and teens with type 2 diabetes are more likely to receive insulin than newer GLP-1 receptor agonists, according to a new study published in Pediatrics. Current guidelines from the American ...

PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...

SGLT2is showed a lower 5-year risk of CKD and fewer AKI events compared to GLP-1 RAs in type 2 diabetes patients. The study utilized Danish registry data, including 55,061 participants, with balanced ...

About The Study: In this systematic review and meta-analysis of 18 trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly improved glycemic, weight, and cardiometabolic outcomes ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

When used as first-line therapy in patients with type 2 diabetes (T2D), GLP-1 receptor agonists (RAs) seemed to be more effective than metformin at reducing the risk for dementia, particularly ...

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.

Telisotuzumab adizutecan (ABBV-400; Temab-A) monotherapy vs trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer with increased c-Met protein expression: An ...